Thrombin Decrease in Thrombin Generation after Heparin Administration in a Homozygous Type II Heparin-Binding Site Antithrombin-Deficient Pregnant Woman

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F23%3A10468999" target="_blank" >RIV/00064165:_____/23:10468999 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/23:10468999

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=U4vRkFTrH9" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=U4vRkFTrH9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1159/000533801" target="_blank" >10.1159/000533801</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Thrombin Decrease in Thrombin Generation after Heparin Administration in a Homozygous Type II Heparin-Binding Site Antithrombin-Deficient Pregnant Woman

Popis výsledku v původním jazyce

Objectives: There is a major problem in providing prophylactic treatment in antithrombin (AT)-deficient pregnant women with a homozygous mutation of the heparin binding site (HBS) and AT level of 17 %. The aim of the study was to determine the effectiveness of heparin by monitoring changes in thrombin generation (TG) in vitro so that pregnant women are not exposed to stress in vivo. Methods: We used the chromogenic method for determination of factor Xa (FXa) inhibition for enoxaparine, nadroparine, dalteparine, fondaparinux and unfractionated heparin (UFH) and the Thrombin Generation Assay (TGA). Results: We found that the degree of inhibition is very different when different heparins are compared. Nadroparin reduces TG the most compared to low molecular weight heparins (LMWH).Conclusion: Routine monitoring of anti FXa activity should be supplemented with TG monitoring, where the effect of LMWH does not manifest itself as this could help in estimating thrombophilic risk during pregnancy.

Název v anglickém jazyce

Thrombin Decrease in Thrombin Generation after Heparin Administration in a Homozygous Type II Heparin-Binding Site Antithrombin-Deficient Pregnant Woman

Popis výsledku anglicky

Objectives: There is a major problem in providing prophylactic treatment in antithrombin (AT)-deficient pregnant women with a homozygous mutation of the heparin binding site (HBS) and AT level of 17 %. The aim of the study was to determine the effectiveness of heparin by monitoring changes in thrombin generation (TG) in vitro so that pregnant women are not exposed to stress in vivo. Methods: We used the chromogenic method for determination of factor Xa (FXa) inhibition for enoxaparine, nadroparine, dalteparine, fondaparinux and unfractionated heparin (UFH) and the Thrombin Generation Assay (TGA). Results: We found that the degree of inhibition is very different when different heparins are compared. Nadroparin reduces TG the most compared to low molecular weight heparins (LMWH).Conclusion: Routine monitoring of anti FXa activity should be supplemented with TG monitoring, where the effect of LMWH does not manifest itself as this could help in estimating thrombophilic risk during pregnancy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30100 - Basic medicine

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Medical Principles and Practice

ISSN

1011-7571

e-ISSN

1423-0151

Svazek periodika

32

Číslo periodika v rámci svazku

4-5

Stát vydavatele periodika

KW - Kuvajtský stát

Počet stran výsledku

5

Strana od-do

308-312

Kód UT WoS článku

001067759000001

EID výsledku v databázi Scopus

2-s2.0-85179079154